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Abstract
Background: The Screening Inventory of Psychosocial Problems (SIPP) is a short, validated self-
reported questionnaire to identify psychosocial problems in Dutch cancer patients. The one-page
24-item questionnaire assesses physical complaints, psychological complaints and social and sexual
problems. Very little is known about the effects of using the SIPP in consultation settings. Our study
aims are to test the hypotheses that using the SIPP (a) may contribute to adequate referral to
relevant psychosocial caregivers, (b) should facilitate communication between radiotherapists and
cancer patients about psychosocial distress and (c) may prevent underdiagnosis of early symptoms
reflecting psychosocial problems. This paper presents the design of a cluster randomised controlled
trial (CRCT) evaluating the effectiveness of using the SIPP in cancer patients treated with
radiotherapy.
Methods/Design: A CRCT is developed using a Solomon four-group design (two intervention
and two control groups) to evaluate the effects of using the SIPP. Radiotherapists, instead of cancer
patients, are randomly allocated to the experimental or control groups. Within these groups, all
included cancer patients are randomised into two subgroups: with and without pre-measurement.
Self-reported assessments are conducted at four times: a pre-test at baseline before the first
consultation and a post-test directly following the first consultation, and three and 12 months after
baseline measurement. The primary outcome measures are the number and types of referrals of
cancer patients with psychosocial problems to relevant (psychosocial) caregivers. The secondary
outcome measures are patients' satisfaction with the radiotherapist-patient communication,
psychosocial distress and quality of life. Furthermore, a process evaluation will be carried out. Data
of the effect-evaluation will be analysed according to the intention-to-treat principle and data
regarding the types of referrals to health care providers and patient satisfaction about the with
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radiotherapists will be analysed by means of descriptive techniques. The process evaluation data
will also be analysed by means of descriptive techniques.
Discussion: Using the SIPP may prevent underdiagnosis of early symptoms reflecting psychosocial
problems, should facilitate communication between physicians and patients about psychosocial
distress and may contribute to adequate referral to relevant (psychosocial) caregivers.
Trial Registration: NCT00859768
Background
Cancer is a leading cause of death worldwide, accountable
for 7.9 million deaths (around 13% of all deaths) in 2007
[1]. Cancer and its treatment may lead to psychosocial dis-
tress involving symptoms of depression and anxiety, and
turmoil in the lives of patients and their families [2,3].
Patients entering radiotherapy treatment (RT) suffer from
specific distress such as fear of RT and its side effects [4].
The prevalence rates of psychosocial distress in cancer
patients as reported in numerous studies vary from 5 to
53%, depending on the study population and the method
of distress assessment [3,5-10].
Nevertheless, psychosocial distress in cancer patients is
often underdiagnosed by medical staff in oncology set-
tings [11,12]. Recognition and treatment of psychosocial
distress in cancer patients is crucial [12,13]. Even when
psychosocial distress is on a sub-clinical level, it should be
managed to prevent further deterioration to psychiatric
disorders like major depression or adjustment disorder
[10]. Psychiatric disorders affect many oncology out-
comes, such as compliance with therapy and quality of life
[12]. Effective treatment of psychosocial distress may
affect the course of the disease and improve patients' qual-
ity of life [13,14]. Therefore, it is important to identify and
treat cancer patients with psychosocial distress at an early
stage.
Validated screening instruments are useful tools to recog-
nise psychosocial distress in cancer patients [2]. Besides
recognition of psychosocial distress, self-reported ques-
tionnaires have proven to be good instruments to facili-
tate communication between patients and physicians
with respect to psychosocial distress [12,15]. Although a
number of well-validated screening instruments exist,
including the Hospital Anxiety and Depression Scale [16],
the Brief Symptom Inventory [5] and the General Health
Questionnaire [17], these instruments require time and
effort in administering and scoring, which may prevent
their systematic use in clinical oncology settings [7,18,19].
Feasible screening instruments should meet the following
criteria: be very brief, preferably fitting on one page[20];
be easy to complete (to avoid further distress by excessive
questioning) [21]; be easy to score and interpret by medi-
cal staff [22]; and facilitate communication between phy-
sicians and patients about psychosocial distress [12,15].
The Screening Inventory Psychosocial Problems (SIPP) is
a valid and reliable Dutch questionnaire (see methods
section). The SIPP was specifically developed for use in
Dutch cancer patients and for measuring a variety of dis-
tress symptoms [23].
Although the SIPP is being used in several hospitals and
health care facilities in the Netherlands, there is still little
known about the effects of using this questionnaire in
consultation settings [23]. Therefore, we performed a
study to assess the effectiveness of the SIPP in a clinical
oncology setting. This paper presents the design of a clus-
ter randomised controlled trial (CRCT) evaluating the
effectiveness of using the SIPP in Dutch patients with the
most common cancer types treated with radiotherapy.
Aims
Primary aims are to study the effect of the SIPP on the
number and types of referrals of cancer patients with psy-
chosocial problems to psychosocial caregivers. Secondary
aims are to study the effects of the SIPP on: 1) patients' sat-
isfaction with the radiotherapist-patient communication
during first consultation, 2) psychological distress in both
the short- and long-term, and 3) quality of life in both the
short- and long-term. Additionally, a process evaluation
will be performed. The aim of the process evaluation is to
gain insight into factors potentially influencing the effec-
tiveness of the SIPP and factors facilitating future imple-
General description of the Solomon four-group design [53] Figure 1
General description of the Solomon four-group 
design [53]. O: Observation. X: Intervention.
 
           Time   
 Period  1 
(pre) 
 
 Period  2 
(post) 
Experimental group  O1 X O2 
Control group   O3   O 4 
Experimental group     X  O5 
Control group       O6 BMC Cancer 2009, 9:177 http://www.biomedcentral.com/1471-2407/9/177
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mentation of the SIPP in oncology care settings, if the
SIPP proves to be effective.
Methods/Design
Study Design
The design of this study is a CRCT because it is less prone
to contamination bias [24-26]. In addition, we used a
Solomon four-group design. The Solomon four-group
design is an experimental design with two experimental
groups and two control groups (Figure 1). Pre-test meas-
ures are used for one experimental and one control group.
Following exposure of both experimental groups to the
intervention, post-test measures are assessed in all four
groups.
Intervention
The SIPP is a short, valid and reliable 24-item self-
reported questionnaire that systematically identifies psy-
chosocial problems in Dutch cancer patients. The psycho-
metric properties of the SIPP were studied in an as yet
unpublished study (submitted, copy available upon
request). This questionnaire was originally developed in
the Netherlands by Pruyn and colleagues in 1997 (then
named the Integral Checklist) [23], and was further
adapted in several Dutch pilot studies [20,27]. The SIPP
assesses:
￿ physical complaints (seven items, score range 0–14),
￿ psychological complaints (10 items, score range 0–
20),
￿ social and financial problems (four items, score
range 0–8), and
￿ sexual problems (three items, score range 0–6 with
an additional option of "not applicable" (N/A)).
Items are rated on a three-point scale of 0 (no) to 2 (yes).
Higher scores indicate poorer functioning.
Before the start of the study, the radiotherapists in the
experimental condition are trained in using and interpret-
ing the SIPP. According to the intervention procedure, the
patient receives the SIPP at two different time points dur-
ing their RT period: just before the first consultation with
the radiotherapist (one to three weeks before starting RT)
and before the last consultation with the radiotherapist at
the end of the RT period (five to nine weeks after complet-
ing the first SIPP). At both times, the completed SIPP is
handed to the radiotherapist at the start of the consulta-
tion. The radiotherapist checks the scores of the SIPP to
get an overview of potential psychosocial problems and
the patient's needs for psychosocial care. Psychosocial
problems are discussed with the patient during the con-
sultation. Referral to a psychosocial caregiver at the Insti-
tute Verbeeten in Tilburg occurs only with the permission
of the patient.
Care as usual
Patients in the control group receive care as usual. No
recent guidelines for the systematic assessment of psycho-
social problems in cancer patients exist at the Institute
Verbeeten. In the control group, radiotherapists may refer
patients to psychosocial caregivers (social workers) at the
Institute Verbeeten. However, this occurs according to the
radiotherapist's judgment about the presence or absence
of psychosocial problems in patients. Referrals to psycho-
social caregivers at the Institute Verbeeten will be regis-
tered in both the patient's records and by the psychosocial
caregivers.
Recruitment of the study population
Recruitment of cancer patients takes place at the Institute
Verbeeten, a radiation oncology department in Tilburg,
the Netherlands. Only cancer patients receiving RT are eli-
gible for this study.
The following inclusion criteria are used: 1) patients with
the most common cancer types such as lung, prostate,
bladder, rectum, breast, cervix, endometrial, skin carci-
noma and Non-Hodgkin; 2) patients 18 years of age or
older and 3) patients with no metastases. Exclusion crite-
ria are: 1) patients receiving palliative treatment, ≤ 10 frac-
tions of RT; 2) patients unable to read and speak Dutch
and 3) patients unable to complete questionnaires.
Patients who meet the inclusion criteria are sent informa-
tion about the study. Those willing to participate in the
study are asked to sign a consent form and are only
allowed to participate after completing and returning it.
Randomisation and stratification
To reduce contamination bias, radiotherapists, instead of
patients, are randomly allocated to the experimental or
control groups. First, the radiotherapists are stratified
according to the general percentages of incoming patients
they referred to a (psychosocial) caregiver in the period
2006–2007. Within their stratum, they are either ran-
domly assigned to the experimental or to the control con-
dition (see Figure 2). Thus, in both conditions there are
equal numbers of radiotherapists who previously referred
relatively more and less cancer patients to (psychosocial)
caregivers. Patients are linked to their radiotherapist.
Therefore, they are randomised to the experimental con-
dition with or without pre-measurement or to the control
condition with or without pre-measurement through
their radiotherapist (see Figure 2). Patients who visit their
radiotherapists in odd weeks are assigned to the experi-
mental/control condition with a pre-measurement and
patients who visit their radiotherapists in even weeks areBMC Cancer 2009, 9:177 http://www.biomedcentral.com/1471-2407/9/177
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assigned to the experimental/control condition without a
pre-measurement. Radiotherapists of the experimental
condition are asked not to discuss this study with their
colleagues of the control condition.
Sample size and power analysis
This study is powered on the primary outcome measures,
i.e. the effect of the SIPP on the number and types of refer-
rals of patients with psychosocial problems to relevant
(psychosocial) caregivers. Sample size calculation shows
that 92 patients per condition are required to compare the
number of referred patients to (psychosocial) caregivers
between conditions with a 80% power and a significance
level of 0.05 (one-sided) [28]. This calculation is based on
results reported by Pruyn and colleagues [23]. In their
study, the use of the Integral Checklist resulted in more
referrals from 2 to 11%. This means that for our study a
total of 368 patients have to be included for the analyses.
The consequence of adopting a CRCT is that the outcome
for each patient can no longer be assumed as independent
[26]. Such a lack of independency has implications for
study size and power [29]. The standard sample size has
to be inflated to take account of the cluster design by using
an estimate of the Intra Cluster Correlation [30,25,26,31].
For our study, no appropriate ICC was available. There-
fore, as in the CRCT of Cumming and colleagues [32], we
assume an ICC of 0.005 as appropriate because the vari-
ance of our outcome measurements between clusters can
be considered low compared to the variability between
the patients within a cluster. To retain power, the standard
sample size should be multiplied by the design effect (d,
d = 1+ρ (m-1)), where m is the size of a cluster unit and ρ
the ICC [25,33]. We therefore multiplied our standard
sample size with a design effect (d) of 1.13. With an
expected dropout rate of 20%, the corrected sample size
for the CRCT is determined at 520.
It is to be noted that stratification by baseline value of the
outcome variable decreases the sample size required [31].
In our study, radiotherapists are stratified according to the
general percentages of incoming patients they referred to
a (psychosocial) caregiver. Stratification of this primary
outcome variable reduces the between-cluster variability
in the primary outcome. In a study by Elridge and col-
leagues the sample size required decreases of almost 50%
by using stratification of the primary outcome [31]. To be
on the safe side regarding the power of our study we
decided not to correct for stratification of the radiothera-
pists. Recruitment and data collection is anticipated to
continue for 24 months.
Measures
Outcome measures
Table 1 presents the primary and secondary outcome
measurements and time of assessment.
Primary outcome measures
The primary outcome measures are the number and types
of referrals of patients with psychosocial problems to psy-
Cluster randomised control trial – Solomon four-group design Figure 2
Cluster randomised control trial – Solomon four-group design.
Experimental condition
  EXP1 
Baseline 
Assessment 
130 patients 
(T1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     0                                                                                                                                                          5-9 weeks         3 months                 12months 
520 Patients 
(Linked to 
radiotherapist of 
experimental or 
control group) 
 
SIPP 1 
Randomi
sation of 
patients 
CON1 
Baseline 
Assessment 
130 patients 
(T1) 
CON2 
No Baseline 
Assessment 
130 patients 
EXP2 
No Baseline 
Assessment 
130 patients 
Care as 
usual 
Immediate 
follow-up 
(T2) 
Follow-
up after 
three 
months 
Follow-
up after 
12 
months 
400 
patients 
(T4) 
Care as 
usual 
Randomi
sation of 
patients 
Control group: 
CON 1&2 
7 Clusters/ 
radiotherapists 
Experimental 
group: EXP1&2 
7 Clusters/ 
radiotherapists 
Randomisation     
        of 
radiotherapists 
 
SIPP 2 
14 Clusters/ 
radiotherapists   
Control condition BMC Cancer 2009, 9:177 http://www.biomedcentral.com/1471-2407/9/177
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chosocial workers at the Institute Verbeeten and/or to
external health care providers (e.g. psychologists, psychia-
trists). The number and types of referrals to (psychosocial)
caregivers are measured at three months (T3) and 12
months (T4) after baseline assessment with a self-devel-
oped questionnaire by the patient and from registration
records of the psychosocial caregivers at the Institute Ver-
beeten. This questionnaire comprises eight items on
whether the patient is referred to a psychosocial caregiver
and the types of problems the patient has experienced
(e.g. financial, psychological, and sexual). The psychoso-
cial caregivers at the Institute Verbeeten collect data from
all referred patients, including types of problems, number
of sessions needed and further referral to an external (psy-
chosocial) caregiver.
Secondary outcome measures
The secondary outcomes are classified in three dimen-
sions: 1) patients' satisfaction with the radiotherapist-
patient communication during the first consultation; 2)
extent of psychological symptoms at T3 and T4; and 3)
patients' quality of life at T3 and T4.
Patients' satisfaction with the radiotherapist-patient communi-
cation is measured directly after the first consultation with
the radiotherapist (T2) by the patient completing a self-
developed questionnaire comprising five items. The first
four items measure whether physical complaints, psycho-
logical complaints and social and sexual problems were
discussed with the radiotherapist (item range 1 (yes) to 3
(no) plus "not applicable"). The fifth item measures the
patient's general opinion (item range 1 (very bad) to 6
(very good)) about the communication with the radio-
therapist during the first consultation.
The extent of psychological symptoms is measured with the
Hospital Anxiety and Depression Scale (HADS) [16] and
the Goldberg's General Health Questionnaire-12 item ver-
sion (GHQ-12) [17]. Patients complete these self-
reported questionnaires at baseline and at T3 and T4.
The HADS is a valid, reliable and useful instrument [16]
that is widely used in studies among cancer patients [34-
40]. It is considered unbiased by coexisting general medi-
cal conditions because its questions do not refer to
somatic symptoms associated with depression [41]. The
HADS consists of a brief subscale of anxiety and a subscale
of depression. Both subscales comprise seven items. Rat-
ings by patients are made on four-point scales (0–3, with
3 indicating greatest distress). Higher scores on each sub-
scale indicate a greater presence of problems [16,42,43].
The GHQ-12 is a well-validated instrument [17] that has
been used in numerous studies among cancer patients
[34,36,44,45]. It is a standardised measure of psychiatric
morbidity across a wide range of patients [43]. It was
intended for use in general practice settings as a screening
instrument for detecting verifiable psychiatric morbidity
(generally anxiety and depression). It measures "usual
state" rather than chronic (long-term) problems [43]. The
GHQ assesses with 12 items whether the patient considers
him- or herself better, the same, worse or much worse over
the previous four weeks than he/she "usually" is. Those
who indicate that their symptoms are unchanged or have
decreased receive a score of 0, while those who report that
their symptoms have increased receive a score of 1. Total
scores range from 0 to 12 [17].
Quality of life is measured using the European Organisa-
tion for Research and Treatment of Cancer, Quality of life
Table 1: Primary and secondary outcome measures of the effect evaluation
Variables N o .  o f  i t e m s T 1T 2T 3T 4
Primary outcome measures:
Number and types of referrals 8/NA - - Q Q/DR
Secondary outcome measures:
Patients' satisfaction with the radiotherapist-patient communication 5 - Q - -
Extent of psychological symptoms:
Symptoms of anxiety and depression (HADS) 14 Q - Q Q
General psychological distress (GHQ-12) 12 Q - Q Q
Quality of life (EORTC QLQ-C30) 30 Q - Q Q
Additional variables:
Socio-demographic variables 4 - Q - -
Medical variables 4 - - - DR
T1: Before first consultation (baseline, only groups with pre-measurement); T2: After consultation;
T3: Three months after baseline; T4: 12 months after baseline; N/A: not applicable; Q: questionnaire:
DR: data record.
HADS: Hospital Anxiety and Depression Scale [16]; GHQ-12: General Health Questionnaire-12 items [17];
EORTC QLQ-C30: European Organisation for Research and Treatment of Cancer,
Quality of life Questionnaire 30 items [46].BMC Cancer 2009, 9:177 http://www.biomedcentral.com/1471-2407/9/177
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Questionnaire (EORTC QLQ-C30) [46]. The EORTC
QLQ-C30 is validated and widely used [30,47-50]. It is a
30-item cancer-specific measure that assesses health-
related quality of life. The EORTC QLQ-C30 comprises:
￿ five functional subscales: physical (five items), role
(two items), emotional (four items), cognitive (two
items) and social functioning (two items);
￿ a subscale about global health status and quality of
life during the past week (two items);
￿ three symptom scales: nausea/vomiting (two items),
fatigue (three items) and pain (two items); and
￿ six single items measuring appetite loss, insomnia,
constipation, diarrhoea, dyspnoea and financial diffi-
culties due to illness or treatment.
The items on the five functional scales and three symptom
scales have four-point response choices of 1 (not at all), 2
(a little), 3 (quite a bit) and 4 (very much). Categories 3
and 4 are regarded as indicators of clinically-significant
symptom levels. Both items of the subscale about global
health status and quality of life use a seven-point visual
analogue scale (VAS) ranging from 1 (very poor) to 7
(excellent) [43]. Patients completed the self-reported
questionnaire EORTC QLQ-C30 at baseline and at T3 and
T4.
Additional variables
Socio-demographic and medical variables are gathered to
provide insight into the characteristics of the sample and
to interpret the outcomes of the study.
Socio-demographic variables age, gender, marital status and
educational level are assessed directly after the first con-
sultation with the radiotherapist (T2).
Medical variables before RT include cancer site, adjuvant
chemo-treatment, TNM-classification and Karnofsky Per-
formance Index (KPI). The TNM-classification is a system-
atic way of describing the size, location and spread of a
tumour. Once established, it must remain unchanged in
the patient's record because the definitive TNM-classifica-
tion is determined just before either initiation of treat-
ment or making the decision not to treat [51]. The KPI
emphasises physical performance and dependency. The
scale is weighted towards physical dimensions of quality
of life rather than social and psychological dimensions.
Patients are assigned to categories by a physician. The KPI
takes no account of the patient's feelings. The KPI varies
from 100 (normal, no complaints, no evidence of disease)
to 0 (dead) [43]. Medical data are extracted from patient
records.
Process evaluation
The aim of the process evaluation is to gain insight into
factors potentially influencing the effectiveness of using
the SIPP and factors facilitating future implementation of
the SIPP. Process evaluation data are collected using self-
developed questionnaires completed by patients of the
intervention groups directly after their first consultation
with the radiotherapist and by radiotherapists directly
after the first consultation and twice during the total
recruitment period of patients. Table 2 provides a short
overview of process evaluation measures. The process
evaluation outcome measures are:
￿ nine items on the opinion of radiotherapists about
the usefulness of the SIPP in general, e.g. "Did you
find discussing the SIPP with the patient useful?"
(item range 0 (not useful) to 10 (very useful));
￿ four items on the opinion of radiotherapists about
the usefulness of the SIPP after each consultation with
a specific patient, e.g. "How much extra time (in min-
utes) does discussing the results of the SIPP take?";
￿ opinion of the patients about the usefulness of the
SIPP after the first consultation, e.g. "Did you find dis-
cussing the SIPP with the radiotherapist useful?" (item
range 0 (not useful) to 10 (very useful); and
￿ two open questions for suggestions for improvement
of the intervention or other remarks.
Table 2: Outcome measures of the process evaluation
Variables No. of items T1 T2 T3 T4
Radiotherapists' opinion about the usefulness of the SIPP in general 9 - - - Q
Radiotherapists' opinion about the usefulness of the SIPP after first consultation 4 - Q - -
Radiotherapists' suggestions for improvement of the intervention or other remarks 2 - - - Q
Patients' opinion about the usefulness of the SIPP after first consultation 3 - Q - -
Patients' suggestions for improvement of the intervention or other remarks 2 - Q - -
T1: Before first consultation (baseline, only groups with pre-measurement); T2: After consultation;
T3: Three months after baseline; T4: 12 months after baseline; Q = questionnaire.BMC Cancer 2009, 9:177 http://www.biomedcentral.com/1471-2407/9/177
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Statistical analysis
Descriptive techniques will be used to describe patients'
background characteristics. To detect potential differences
between the experimental and control groups at the start
of the study, the baseline levels of psychological distress
and quality of life will be compared. Furthermore, to iden-
tify potential differences between the two experimental
groups and the two control groups (both with and with-
out pre-measurement) at T3 the extent of psychological
distress and quality of life will be compared. If these latter
differences emerge, the four groups need to be handled
separately in the analyses, i.e. the experimental and con-
trol groups with pre-measurement and the experimental
and control groups without pre-measurement will be
compared separately. If not, the two experimental groups
and the two control groups will be combined in one
group.
Data of the effect evaluation will be analysed according to
the intention-to-treat principle. Univariate, multivariate
and descriptive techniques are applied to estimate the
effect of the intervention by comparing the experimental
with the control groups with regard to the primary and
secondary outcomes at the follow-up measurements and
by comparing the pre-test (T1) with post-tests (T3 and
T4). Potential confounding factors and baseline differ-
ences will be checked and included in the model if neces-
sary. Since dependency between outcome variables from
the same cluster may exist, as well as between repeated
measurements within patients, multilevel modelling will
be carried out. Furthermore, multilevel modelling mini-
mizes the loss of data through dropout by including all
available data from participants in the analyses. Dropout
will be described.
The process evaluation data (collected from radiothera-
pists and patients of the experimental groups) will be ana-
lysed by means of descriptive techniques.
Ethics
The Medical Ethics Committee of the Twee Steden Hospi-
tal in Tilburg, the Netherlands, granted approval for con-
ducting this study.
The protocol is registered in the ClinicalTrials.gov register
number NCT00859768.
Discussion
This study will provide insight into the actual systematic
effects of using the SIPP in consultation settings. It is
important to know the possible effects of using the SIPP
on aspects such as communication between physicians
and patients, early recognition and treatment of psycho-
social problems, the extent and severity of experienced
psychological problems among cancer patients and the
quality of life of patients over a long period. Until now,
there have been no RCTs on the effectiveness of the SIPP
on aspects such as quality of life among cancer patients
and the extent of psychological distress that cancer
patients experience over a long period after the initial radi-
ation or other treatment of the cancer. Until now, there
have also been no reports on the differences in number of
patients receiving psychosocial help because of using the
SIPP.
The design of this study is a CRCT. Cluster randomisation
is applied because randomisation at the patient level may
jeopardise the validity of the study since patients of the
experimental and control conditions may visit the same
radiotherapist for consultation. Furthermore, radiothera-
pists may alter their communication style, attitude or may
pay more attention to patients' psychosocial distress
because of using the SIPP. The Solomon four-group
design is chosen in order to check for potential pre-meas-
urement effects on intervention outcomes [52,53].
In this study, we decided to include patients with the most
common cancer types and with a reasonably good prog-
nosis because patients were asked to complete question-
naires 12 months after baseline measurement.
One limitation of this study is that the results can not be
generalised to all Dutch cancer patients since our study
population consisted of cancer patients that received RT.
Further studies outside the radiotherapy setting would be
required to generalise the results.
Future implementation
Using the SIPP may prevent underdiagnosis of early
symptoms reflecting psychosocial problems and may con-
tribute to adequate referrals to psychosocial caregivers.
Therefore, using the SIPP may lead to a reduction of psy-
chological problems and a better quality of life among
Dutch cancer patients in both the short- and long-term. If
the SIPP proves to be effective, the results of this study
may help motivate physicians to use the SIPP as a stand-
ard method for early detection of psychosocial problems
in oncology departments in the Netherlands and abroad.
Progress of the study
Recruitment of eligible patients commenced in April 2008
and will end in July 2009, resulting in 520 eligible
patients being included in the study. The follow-up period
will continue until July 2010. Results will be published in
relevant journals.
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